Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type  2 Diabetes
ConclusionsBT-001 plus SoC was estimated to dominate SoC alone over the lifetime horizon from a payer perspective, suggesting that using BT-001 can empower patients to better manage their diabetes with the potential for lifelong advantages. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research

TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort
ConclusionThis is the first study in Colombia (TIROSEC) to our knowledge that integrates molecular and histopathologic profiles enriching our local comprehension and knowledge of PTC. The identification of target mutations such asBRAF,RET andNTRK fusions holds the potential to guide targeted therapies for tumor recurrence and predict aggressive behavior. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research

Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years
This study supports the effectiveness of Oleogel-S10 in a real-world scenario in a country with scarce resources for the trea tment of EB. (Source: Advances in Therapy)
Source: Advances in Therapy - January 3, 2024 Category: Drugs & Pharmacology Source Type: research

Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis  C and Cirrhosis
ConclusionAn 8-week regimen of GLE/PIB is well tolerated and highly effective among US patients with HCV and cirrhosis receiving routine clinical care. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study
ConclusionsWe identified a glaucoma subgroup in which PR decreased, choroidal blood flow increased, and glaucoma progression slowed after a β-blocker eye drop add-on was started. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
ConclusionResponse to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

Immune Cell Alterations and PI3K-PKB Pathway Suppression in Patients with Allergic Rhinitis Undergoing Sublingual Immunotherapy
ConclusionOur study has demonstrated that SLIT treatment led to distinct changes in immune cell profiles between mono-sensitized and poly-sensitized AR patients. Furthermore, SLIT appeared to reduce a Th2 immune response, highlighting its efficacy in AR treatment. Importantly, the study revealed the suppression of the PI3K-PKB pathway, shedding light on the immunological mechanisms underlying SLIT ’s effectiveness. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
ConclusionMost studies suggested that upadacitinib has no statistically significant difference in the studied safety outcomes compared to active treatments or placebo in patients with RA, PsA, AS, AD, UC, and CD. A few studies reported higher rates, but findings were inconsistent with limited interpretation. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study
ConclusionThe majority of patients from this real-world dataset underwent FoundationOne®CDx testing after initiation of first-line treatment. Testing appeared to influence treatment patterns, with a higher proportion of patients with BRCAm, HRRm, and HRD-positive disease receiving PARP inhibitors. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research

Liver Dysfunction in Adult Hemophagocytic Lymphohistiocytosis: A Narrative Review
AbstractHemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition that has been increasingly recognized in adults and is characterized by a hyperinflammatory state due to immune dysregulation. Its nonspecific presentation, the lack of clinician familiarity given its rarity, and shared clinical features with sepsis and other syndromes can lead to a delay in diagnosis and a poor prognosis. Significant liver function abnormalities as the initial manifestation of HLH are uncommon and can range from mild elevation of aminotransferases to fulminant hepatic failure with high mortality rates. The authors encou...
Source: Advances in Therapy - December 25, 2023 Category: Drugs & Pharmacology Source Type: research

Correction to: A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance
(Source: Advances in Therapy)
Source: Advances in Therapy - December 21, 2023 Category: Drugs & Pharmacology Source Type: research

Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
ConclusionHigher BMI is associated with greater deficits in hedonic tone in persons with PCC, which may impact reward functioning processes such as reward prediction and processing. The mediatory effect of BMI on reward function underscores the need to investigate the neurobiologic interactions to elucidate preventative and therapeutic interventions for persons with PCC. Therapeutic development targeting debilitating features of PCC (e.g., motivation, cognitive dysfunction) could consider stratification on the basis of baseline BMI.Trial Registration NumberNCT05047952. (Source: Advances in Therapy)
Source: Advances in Therapy - December 19, 2023 Category: Drugs & Pharmacology Source Type: research

Machine Learning Approaches to Predict Asthma Exacerbations: A Narrative Review
AbstractThe implementation of artificial intelligence (AI) and machine learning (ML) techniques in healthcare has garnered significant attention in recent years, especially as a result of their potential to revolutionize personalized medicine. Despite advances in the treatment and management of asthma, a significant proportion of patients continue to suffer acute exacerbations, irrespective of disease severity and therapeutic regimen. The situation is further complicated by the constellation of factors that influence disease activity in a patient with asthma, such as medical history, biomarker phenotype, pulmonary function...
Source: Advances in Therapy - December 19, 2023 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness and Budget Impact Analyses of Patient Blood Management in a Cardiovascular Surgery Department at Ankara Bilkent City Hospital in Turkey
ConclusionThis hospital-based study demonstrated that PBM is a budget-saving and cost-effective option in Turkey. (Source: Advances in Therapy)
Source: Advances in Therapy - December 19, 2023 Category: Drugs & Pharmacology Source Type: research

Comparative Effectiveness of Teclistamab Versus Real-World Physician ’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
ConclusionTeclistamab demonstrated significantly improved effectiveness over RWPC in LocoMMotion  ± MoMMent, emphasizing its clinical benefit as a highly effective treatment for patients with TCE RRMM.Trial RegistrationMajesTEC-1, ClinicalTrials.gov NCT03145181 (phase  1) and NCT04557098 (phase 2); LocoMMotion, ClinicalTrials.gov NCT04035226; MoMMent, ClinicalTrials.gov NCT05160584. (Source: Advances in Therapy)
Source: Advances in Therapy - December 19, 2023 Category: Drugs & Pharmacology Source Type: research